Health & Environmental Research Online (HERO)


Print Feedback Export to File
2729079 
Journal Article 
Response of refractory Hodgkin's disease to monoclonal anti-CD30 immunotoxin 
Falini, B; Bolognesi, A; Flenghi, L; Tazzari, PL; Stirpe, F; Et al 
1992 
1 
The Lancet
ISSN: 0140-6736
EISSN: 1474-547X 
IPA/92/1013064 
VOL 339 ISS May 16 1992 
REF 10 
1195-1196 
English 
IPA COPYRIGHT: ASHP The possible therapeutic role of an immunotoxin prepared by covalent linking of an anti-CD30 monoclonal antibody to saporin, a type-1 ribosome-inactivating protein, was studied in 4 patients with advanced refractory Hodgkin's disease who received 0.8 mg/kg of the immunotoxin in one or 2 doses. In 3 patients, there was rapid and substantial reduction in tumor mass (50-70%). Antibodies to both parts of the immunotoxin developed in all patients.